Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.

Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.

Three strong quarters in a row have prompted Nippon Chemiphar to revise up its FY2021 forecasts, thanks to strong sales of generic drugs launched in FY2020 and June 2021, as well as an increase in demand due to quality control issues faced by competitors.